phospho-JNK1 + 2 + 3 (Thr183+Tyr185)抗体特异性结合抗原：抗体本身不能直接溶解或杀伤带有特异抗原的靶细胞，通常需要补体或吞噬细胞等共同发挥效应以**病原微生物或导致病理损伤。然而，抗体可通过与病毒或**的特异性结合，直接发挥中和病毒的作用。
产品编号xy- 1640R
英文名称phospho-JNK1 + 2 + 3 (Thr183+Tyr185)
中文名称磷酸化氨基末端激酶1/2/3抗体
别 名JNK1 + JNK2 + JNK3(phospho T183+T183); JNK1 (phospho T183 + Y185); p-JNK1 (phospho T183 + Y185); MAPK8 (phospho T183/Y185); JNK1 + JNK2 + JNK3 (phospho Thr183+Tyr185); JNK1 + 2 + 3 (phospho Thr183+Tyr185); p-JNK; c Jun N terminal kinase 1; C-JUN kinase 1; EC 2.7.11.24; JAK 1A; JAK1A; JNK 1; JNK 46; JNK; JNK1A2; JNK21B1/2; MAP kinase 8; MAPK 8; MAPK8; Mitogen activated protein kinase 8; p54 gamma; PRKM 8; PRKM8; Protein kinase JNK1; Protein kinase, mitogen-activated, 8; SAPK 1; SAPK gamma; SAPK1; Stress activated protein kinase JNK1; Stress-activated protein kinase JNK1; Tyrosine protein kinase JAK1; AI849689; MK08_HUMAN.
JournalPMIDIFApplicationJournal of Cellular and Molecular Medicine (2013)234807864.7530WBOsteoarthritis and Cartilage (2012)229357884.2620WBPLoS One (2014)244041463.3100WBInternational Immunopharmacology (2016)266441682.4720WBBasic & Clinical Pharmacology & Toxicology (2016)268338672.3770WBOncology Reports (2016)271214202.3000WB
说 明 书100ul
产品类型磷酸化抗体
研究领域肿瘤 **学 信号转导 转录调节因子
抗体来源Rabbit
克隆类型Polyclonal
phospho-JNK1 + 2 + 3 (Thr183+Tyr185)抗体交叉反应 Human, Mouse, Rat, Dog, Pig, Cow,
产品应用ELISA=1:500-1000 IHC-P=1:400-800 IHC-F=1:400-800 Flow-Cyt=1μg /test ICC=1:100-500 IF=1:100-500 （石蜡切片需做抗原修复）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量42kDa
细胞定位细胞核 细胞浆
性 状Lyophilized or Liquid
浓 度1mg/1ml
免 疫 原KLH conjugated Synthesised phosphopeptide derived from human JNK1 around the phosphorylation site of Thr183/Tyr185:MM(p-T)P(p-Y)VV
亚 型IgG
纯化方法affinity purified by Protein A
储 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
phospho-JNK1 + 2 + 3 (Thr183+Tyr185)抗体保存条件Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
PubMedPubMed
产品介绍background:
JNK1 (MAPK8) is a member of the MAP kinase family. MAP kinases act as an integration point for multiple biochemical signals, and are involved in a wide variety of cellular processes such as proliferation, differentiation, transcription regulation and development. This kinase is activated by various cell stimuli, and targets specific transcription factors, and thus mediates immediate-early gene expression in response to cell stimuli. The activation of this kinase by tumor-necrosis factor alpha (TNF-alpha) is found to be required for TNF-alpha induced apoptosis. This kinase is also involved in UV radiation induced apoptosis, which is thought to be related to cytochrome c-mediated cell death pathway. Studies of the mouse counterpart of this gene suggested that this kinase play a key role in T cell proliferation, apoptosis and differentiation. Four alternatively spliced transcript variants encoding distinct isoforms have been reported. JNK1 is activated by threonine and tyrosine phosphorylation by either of two dual specificity kinases, MAP2K4 and MAP2K7. The JNK pathway is critically involved in diabetes and levels are abnormally elevated in obesity. The cell-permeable JNK inhibitory peptide may have promise as a therapeutic agent for diabetes.
Subunit:
Interacts with MECOM and DCLK2. Binds to at least four scaffolding proteins, MAPK8IP1/JIP-1, MAPK8IP2/JIP-2, MAPK8IP3/JIP-3/JSAP1 and SPAG9/MAPK8IP4/JIP-4. These proteins also bind other components of the JNK signaling pathway. Interacts with NFATC4. Interacts with ATF7; the interaction does not phosphorylate ATF7 but acts as a docking site for ATF7-associated partners such as JUN. Interacts with BCL10. Interacts with CTNNB1 and GSK3B.
Subcellular Location:
Cytoplasm. Nucleus.
Post-translational modifications:
Dually phosphorylated on Thr-183 and Tyr-185 by MAP2K7 and MAP2K4, which activates the enzyme. Autophosphorylated in vitro.
Similarity:
Belongs to the protein kinase superfamily. CMGC Ser/Thr protein kinase family. MAP kinase subfamily.
Contains 1 protein kinase domain.
SWISS:
P45983
Gene ID:
5599
phospho-JNK1 + 2 + 3 (Thr183+Tyr185)抗体（antibody,
Ab）是由效应B细胞（效应**B细胞）分泌，机体用于抵御外来物质，如病毒，**等抗原，结构呈“Y”字型的球状蛋白质，仅仅存在于脊椎动物的血液和B**细胞膜表面。凡是能够跟抗体结合的物质，均被称作抗原，因此对于抗抗体（能够结合抗体的抗体）来说，抗体本身也是一种抗原物质。
phospho-JNK1 + 2 + 3 (Thr183+Tyr185)抗体普通抗体重链和轻链的结构
重链结构：普通的**球蛋白具有2条重链（H链），分子量约为50kD,有μ、δ、γ、ε和α五种重链亚型，对应的**球蛋白名称分别为IgM、IgG、IgA、IgD和IgE。
轻链结构： 普通**球蛋白具有2条轻链（L链），分子质量约25kDa，有κ链和λ链两种亚型，这两种轻链决定了Ig的亚型类别（IgG1，IgG2，IgG3，IgG4）。一个天然的Ig分子两条轻链总是相同的，但在同一个体内可存在分别带有κ或λ链的抗体分子。不同种属生物体内两型轻链的比例不同，正常人血清**球蛋白κ链：λ链约为2：1，而在小鼠的比例为20：1。
2.2抗体Fab段和Fc段
IgG经木瓜蛋白酶酶切后裂解为2个完全相同的Fab段和1个Fc段,每个Fab段都为单价,可与抗原结合但不会再发生凝集反应；经胃蛋白酶酶切后裂解为1个完整F(ab)2片段和碎片化的Fc片段,F(ab’)2片段为双价,可同时结合两个抗原表位。Fab段为抗原结合片段（fragment of antigen binding，Fab），相当于抗体分子的两个臂，由一个完整的轻链和重链的VH和CH1结构域组成。Fc段为可结晶段（fragment crystallizable，Fc）相当于Ig的CH2和CH3结构域，是Ig与效应分子或者细胞相互作用的部位。Fab段包含完整的可变区，以及恒定区的CH1区域。Fc段仅指Ig恒定区CH2和CH3的区域，相当于Y字结构下面那一部分。
合格 CYP1B1 细胞色素cP4501B1抗体
合格 CYP19 细胞色素P450 19抗体
合格 CSK 酪氨酸激酶C-SRC抗体
合格 phospho-CSK (Ser364) 磷酸化酪氨酸激酶C-SRC抗体
合格 CSPS/MPST 磺基转移酶CSPS抗体
合格 Desmoplakin I+II 桥粒斑蛋白1+2抗体
合格 phospho-Acetyl Coenzyme A Carboxylase alpha (Ser1263) 磷酸化乙酰辅酶A羧化酶抗体
合格 phospho-ACTH (Ser168) 磷酸化促肾上腺皮质**ACTH抗体
合格 CD28 CD28抗体
合格 phospho-delta 1 Catenin (Ser268) 磷酸化δ连环蛋白抗体
合格 phospho-Dishevelled 2 (Ser143) 磷酸化蓬乱蛋白2抗体
合格 Ubiquitin D 泛素D抗体
合格 DNA polymerase delta p50 DNA聚合酶δ2/DNA pol δ 2抗体
合格 DNA polymerase mu DNA聚合酶μ/DNA pol μ抗体
合格 DNA Polymerase theta/POLH DNA聚合酶θ/DNA pol θ抗体
合格 DNAJA2 细胞周期蛋白3抗体
合格 Dnmt2 DNA甲基转移酶2抗体
合格 Drosha 核糖核酸酶3/Drosha抗体
合格 Dynorphin A 脑啡肽A抗体
合格 DMWD 强直性肌营养**相关蛋白9抗体
合格 DZIP3 E3泛素蛋白连接酶dzip3抗体
合格 EAAT4 胶质细胞谷氨酸运载蛋白4抗体
合格 ECH1 烯酰辅酶A水合酶1抗体
合格 Bad 相关死亡促进因子Bad抗体
合格 合格 EDAR 肿瘤坏死因子受体超家族成员EDAR抗体
合格 UBR5 E3泛素蛋白连接酶EDD抗体
合格 eEF1A2 翻译延伸因子EF-1 α2抗体
合格 EEF1G 延伸因子EF-1 γ抗体
合格 CCR7 细胞表面趋化因子受体7抗体
合格 FABP12 脂肪酸结合蛋白12抗体
合格 PARK7/DJ1 CAP1抗体